Business
Gilead Sciences Inc.’s stock rose Thursday after the biotech company’s Kite Pharma unit gained federal approval for its flagship cell-treatment therapy for adults with advanced lymphoma.
Oct. 19, 2017
AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest healthcare deal on record.
June 7, 2020
Gilead Sciences Inc. will sell cheaper versions of its blockbuster hepatitis C drugs, the original versions of which sparked widespread debate about U.S. pharmaceutical costs when they were introduced at a price of more than $1,000 a pill.
Sept. 24, 2018
Driven by innovative but pricey new drugs for hepatitis C, U.S. spending on prescription drugs jumped 13% last year to a record $374 billion, according to an industry report.
April 14, 2015
The firm would gain an AIDS drug that could receive FDA marketing approval next fall.
Dec. 5, 2002
Technology and the Internet
Gilead Sciences Inc. said it will buy Nexstar Pharmaceuticals Inc. for $550 million in stock, giving Gilead two new drugs and sales teams in Europe and Australia.
March 2, 1999
Gilead Sciences Inc., the world’s third-biggest biotechnology company, said Monday that it had agreed to acquire Myogen Inc. for $2.5 billion in a transaction that gives Gilead access to Myogen’s experimental hypertension drugs.
Oct. 3, 2006
Philadelphia’s transit system is taking on Gilead Sciences Inc. over its sky-high pricing of the breakthrough hepatitis C drug Sovaldi.
Dec. 11, 2014
Gilead Sciences Inc. on Thursday posted a first-quarter profit of $114.4 million as sales rose for its Viread AIDS drug.
April 23, 2004
Santa Monica biotech company Kite Pharma Inc. is being acquired by industry giant Gilead Sciences Inc. in an $11.9-billion deal that demonstrates the promise of using a person’s own immune system to fight cancer.
Aug. 28, 2017